FLNA.US Filana Therapeutics, Inc.

Healthcare Biotechnology USA Stocks
0.4251 USD
Close of Nov 14, 2026
0.4200 3.45
Market cap
USD 21.4M
P/E
-
P/B
0.39x
ROE
-68.2%
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.

Is FLNA.US undervalued?

Graham number

The Graham number of Filana Therapeutics, Inc. cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

Filana Therapeutics, Inc. fundamental analysis

No fundamental analysis for Filana Therapeutics, Inc. yet.

Filana Therapeutics, Inc. stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About Filana Therapeutics, Inc.

Filana Therapeutics, Inc., a clinical stage biotechnology company, develops drugs for neurodegenerative diseases. Its lead therapeutic product candidate is simufilam, a small molecule drug, which is in Phase 3 clinical trial to treat Alzheimer's disease; and investigational diagnostic product candidate is SavaDx, an early-stage program focused on detecting the presence of Alzheimer's disease from a small sample of blood. The company was formerly known as Cassava Sciences, In…

Full company profile